NCT07539688尚未招募1 期
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 18
- 主要终点
- Safety indicators
研究概览
简要总结
This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
详细描述
This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma. It plans to enroll 9-18 participants and uses a "3+3" dose-escalation design (with 3 dose groups: 1×10^6, 2×10^6, and 3×10^6 CAR cells/kg) along with a dose-expansion study to administer CAR-T cell injection. Patients will be followed to observe adverse reactions and collect data on treatment efficacy, evaluating the safety and effectiveness of the CAR-T cell injection. The DLT observation period is 28 days after CAR-T cell infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. The participant has given consent and signed the informed consent form, and is willing and able to comply with the planned visits, research treatments, laboratory tests, and other trial procedures;
- •2. Clinically diagnosed as a patient with relapsed/refractory B-cell lymphoma, and confirmed by pathological and histological examination as CD19 and/or CD22 B-cell lymphoma, including: diffuse large B-cell lymphoma, or transformed large B-cell lymphoma from indolent B-cell lymphoma (excluding Richter transformation, THRLBCL, BL). And meets the following criteria (meets any one of the first three items and the fourth): i. Recurrence ≥6 months after achieving remission with first-line full treatment, or ≥12 months after achieving remission following stem cell transplantation; ii. Progression during first-line treatment combined with high-risk factors (double-expressor lymphoma, double-hit lymphoma, TP53 gene mutation or deletion, IPI score ≥3); iii. Disease relapse after ≥2 lines of treatment or failure to achieve remission; iv. The participant has received the following treatment regimens after being diagnosed with LBCL:
- •Anti-CD20 monoclonal antibody;
- •Combination chemotherapy containing anthracyclines.
- •3. Age 18 or older, both men and women are eligible;
- •4. Study participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- •5. Expected survival of more than 3 months from the date of signing the informed consent;
- •6. HGB ≥ 60 g/L (transfusion allowed); LYM ≥ 0.3×10^9/L;
- •7. Liver and kidney function and cardiopulmonary function must meet the following requirements:
- •Creatinine ≤ 1.5 × ULN;
- •Left ventricular ejection fraction ≥ 50%;
- •Blood oxygen saturation > 90%;
- •Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;
- •8. Participants intending to become pregnant must agree to use contraception before enrollment in the study and for one year after CAR-T cell infusion; if a participant becomes pregnant or suspects pregnancy, they should immediately inform the investigator.
排除标准
- •1. Severe heart failure or left ventricular ejection fraction <50%;
- •2. History of severe pulmonary function impairment;
- •3. Concurrent other malignant tumors in the progressive stage;
- •4. Concurrent severe infection that cannot be effectively controlled;
- •5. Concurrent severe autoimmune disease or congenital immunodeficiency;
- •6. History of CAR-T cell immunotherapy;
- •7. Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA] or hepatitis C virus ribonucleic acid [HCV-RNA] test results above the detection limit);
- •8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.
- •9. A history of severe allergic reactions to biological products (including antibiotics);
- •10. Allogeneic hematopoietic stem cell transplant patients who still have acute graft-versus-host disease (GvHD) one month after stopping immunosuppressive agents;
- •11. Women who are pregnant, breastfeeding, or planning to become pregnant within 12 months;
- •12. Patients with other serious physical or mental illnesses or abnormal laboratory test results that may increase the risk of participating in the study, or interfere with study results, or who are deemed by the investigators to be unsuitable for participation in this study.
研究组 & 干预措施
CY-219 CAR-T
Other
干预措施: CY-219 CAR-T (Drug)
结局指标
主要结局
Safety indicators
时间窗: 6 months after CAR-T infusion
Six months after CAR-T infusion, analyze the recorded possible adverse reactions, mainly including the number of cases, incidence, and severity of immune-related toxicities such as cytokine release syndrome, immune effector cell-associated neurotoxicity, hematologic toxicity, and organ toxicity. The incidence of DLT.
次要结局
- Efficacy indicators(Three months after treatment)
- Cellular Metabolic Kinetics Indicators(On the fourth, seventh, tenth, fourteenth, twenty-first, and twenty-eighth days after retransfusion)
- Cellular Metabolic Kinetics Indicators(Peripheral blood CAR copy number of research participants during follow-up)
- Cellular Metabolic Kinetics Indicators(28 days after treatment)
研究者
相似试验
尚未招募
1 期
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune DiseasesMyasthenia GravisMultiple SclerosisNCT07392528Tianjin Huanhu Hospital15
尚未招募
2 期
Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical ProstatectomyProstate CancerNCT07415135Zhu Yinjie18
招募中
2 期
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
招募中
2 期
NWRD06 DNA Plasmid for HCC After Curative Resection.NCT07324304Newish Technology (Beijing) Co., Ltd.30
尚未招募
2 期
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)NCT07472478Guangdong Provincial People's Hospital32